/
Infectious Disease
Respiratory Syncytial Virus (RSV)
22
Pipeline Programs↗
53
Active Trials↗
28
Companies Involved↗
Respiratory Syncytial Virus (RSV) is an emerging landscape with 22 programs across 28 companies. The most active players are Moderna, Pfizer, MAXVAX Biotechnology Limited Liability Company. 7 programs are in Phase 3.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical8
Phase 13
Phase 24
Phase 37
Approved
No programs
Analysis
Modality Breakdown
60%
Vaccine
6 of 10 classified programs — the dominant modality here.
Vaccine leads; the ring shows all 10 classified programs, each share of the total. Modality classified for 68% of 22 pipeline programs.
Analysis
Trial Status
174
clinical trials
Completed96 · 55%
Active, not recruiting26 · 15%
Terminated18 · 10%
Recruiting17 · 10%
Not yet recruiting10 · 6%
Unknown status3 · 2%
Other4 · 2%
Clinical Trials
Trial Activity
174 trials
A Phase 1, Randomized, Double-Blind, Ascending-Dose Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Respiratory Syncytial Virus mRNA Vaccine YKYY025 Injection in Healthy Adult Participants
Recruiting·BBeijing Youcare Kechuang Pharmaceutical Technology Co., Ltd.·Phase 1·NCT07694557·180 enrolled
Page 1 of 12
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)